$HIMS earnings report

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026; raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million. AlphaAI read Hims & Hers Health's Second Quarter 2026 filing as mixed.

Second Quarter 2026

alphai · Earnings readHIMS · Second Quarter 2026 · ended June 30, 2026

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026; raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million

Mixed quarter

Revenue, subscribers, monthly revenue per average subscriber, and international revenue grew strongly, and the Company raised its full-year revenue outlook. However, gross margin declined, the Company reported a net loss, Adjusted EBITDA declined year-over-year, and operating cash flow and Free Cash Flow remained negative.

Revenue
$753.2 million
38% y/y
United States Revenue, three months ended June 30, 2026
$ 621,830 (In Thousands)
16% y/y
Gross margin · GAAP
64%
Third quarter 2026 and full year 2026 outlook
Third quarter 2026: $880 million to $900 million. Full year 2026: $3.1 billion to $3.3 billion.

Key metrics

as reported
MetricValueq/qy/y
Subscribers (end of period), three months ended June 30, 2026other2,891 (In Thousands)19%
Subscribers (end of period), six months ended June 30, 2026other2,891 (In Thousands)19%
Monthly Revenue per Average Subscriber, three months ended June 30, 2026other$ 9221%
Monthly Revenue per Average Subscriber, six months ended June 30, 2026other$ 844%
Total revenue, three months ended June 30, 2026GAAP$753.2 million38%
Total revenue, six months ended June 30, 2026GAAP$ 1,361,318 (In Thousands)20%
Gross margin, second quarter 2026GAAP64%
Net loss, second quarter 2026GAAP$86.3 million
Adjusted EBITDA, second quarter 2026non-GAAP$60.3 million
Net cash (used in) operating activities, second quarter 2026GAAP$(35.9) million
Free Cash Flow, second quarter 2026non-GAAP$(68.2) million

Segments

SegmentRevenueq/qy/y
United States Revenue, three months ended June 30, 2026The CFO said domestic revenue growth accelerated to 16% year-over-year and that the domestic business is expected to continue accelerating through the second half of the year.$ 621,830 (In Thousands)16%
Rest of the World Revenue, three months ended June 30, 2026The CFO attributed international growth to the close of the Eucalyptus acquisition in June.131,384 (In Thousands)1,641%
United States Revenue, six months ended June 30, 2026No additional six-month segment driver was quantified.$ 1,151,739 (In Thousands)3%
Rest of the World Revenue, six months ended June 30, 2026The CFO said the international business was strengthened by the close of the Eucalyptus acquisition in June.209,579 (In Thousands)1,310%

Third quarter 2026 and full year 2026 outlook

  • RevenueThird quarter 2026: $880 million to $900 million. Full year 2026: $3.1 billion to $3.3 billion.
  • NoteThird quarter 2026 Adjusted EBITDA: $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.
  • NoteFull year 2026 Adjusted EBITDA: $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.

What drove it

  • Revenue was $753.2 million, up 38% year-over-year.
  • Subscribers grew to 2,891 (In Thousands), up 19% year-over-year.
  • Monthly Revenue per Average Subscriber was $ 92, up 21% year-over-year.
  • United States Revenue was $ 621,830 (In Thousands), up 16% year-over-year.
  • Rest of the World Revenue was 131,384 (In Thousands), up 1,641% year-over-year.
  • The CFO said the international business was strengthened by the close of the Eucalyptus acquisition in June.
  • The Company raised full-year 2026 revenue guidance to $3.1 billion to $3.3 billion.

Concerns

  • Gross margin was 64% compared to 76% for the second quarter of 2025.
  • Net loss was $86.3 million compared to net income of $42.5 million for the second quarter of 2025.
  • Adjusted EBITDA was $60.3 million compared to $82.2 million for the second quarter of 2025.
  • Net cash (used in) operating activities was $(35.9) million compared to $(19.1) million for the second quarter of 2025.
  • Free Cash Flow was $(68.2) million.

What to watch

  • Third-quarter revenue guidance of $880 million to $900 million.
  • Third-quarter Adjusted EBITDA guidance of $75 million to $95 million and Adjusted EBITDA margin guidance of 9% to 11%.
  • Management's expectation that the domestic business will continue accelerating through the second half of the year.
  • International expansion following the close of the Eucalyptus acquisition in June.
  • Gross margin, which was 64% in the second quarter of 2026 compared to 76% in the second quarter of 2025.
  • Operating cash flow and Free Cash Flow, which were negative in the second quarter of 2026.

Balance sheet and cash flow

  • Net cash (used in) operating activities was $(35.9) million for the second quarter of 2026 compared to $(19.1) million for the second quarter of 2025.
  • Free Cash Flow was $(68.2) million for the second quarter of 2026 compared to $(69.4) million for the second quarter of 2025.

Analysis

Hims & Hers reported $753.2 million of second-quarter revenue, up 38% year-over-year, with subscribers of 2,891 (In Thousands), up 19%, and Monthly Revenue per Average Subscriber of $ 92, up 21%. The combination of subscriber growth and higher monthly revenue per average subscriber supported the quarter's top-line expansion. The Company described this as a re-acceleration in its growth profile.

Revenue growth was led by Rest of the World Revenue of 131,384 (In Thousands), up 1,641% year-over-year, while United States Revenue of $ 621,830 (In Thousands) grew 16%. Management said the international business was strengthened by the close of the Eucalyptus acquisition in June. The CFO also said domestic revenue growth accelerated to 16% year-over-year and expects the domestic business to continue accelerating through the second half of the year.

Profitability and cash generation were weaker than the revenue trajectory. Gross margin was 64%, compared with 76% in the prior-year quarter. The Company reported a net loss of $86.3 million, versus net income of $42.5 million, while Adjusted EBITDA was $60.3 million, compared with $82.2 million. Net cash used in operating activities was $(35.9) million and Free Cash Flow was $(68.2) million. The release does not provide prior-quarter figures for these metrics, so quarter-over-quarter changes cannot be assessed from the filing.

Management raised full-year 2026 revenue guidance to $3.1 billion to $3.3 billion and updated full-year Adjusted EBITDA guidance to $275 million to $325 million, with an Adjusted EBITDA margin of 9% to 10%. Third-quarter guidance calls for revenue of $880 million to $900 million and Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%. The central items for investors are whether domestic acceleration and acquired international scale translate into the guided revenue range while gross margin, Adjusted EBITDA, and cash flow improve.

Management, verbatim

Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive.

Andrew Dudum, co-founder and CEO

Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform.

Yemi Okupe, Chief Financial Officer

Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June.

Yemi Okupe, Chief Financial Officer

Not in the filing

stated, not guessed
  • Previous-quarter revenue, segment revenue, subscriber, Monthly Revenue per Average Subscriber, gross margin, net income or loss, Adjusted EBITDA, operating cash flow, and Free Cash Flow figures were not provided.
  • GAAP operating income was not provided.
  • GAAP diluted EPS and non-GAAP diluted EPS were not provided.
  • Cash balance and debt balance were not provided.
  • Share repurchases, dividends, and other capital-return figures were not provided.
  • Guidance for gross margin, operating expenses, and tax rate was not provided.
  • A previous-quarter outlook was not provided, so reported results cannot be compared with prior guidance.
  • A quantitative reconciliation of forward-looking Adjusted EBITDA to net income or loss was not provided.

AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about HIMS earnings dates

When is Hims & Hers Health's next earnings date?
AlphaAI has no confirmed date for HIMS yet. We publish an earnings date only once the company has set it, so this page shows one the day that happens.
Where does the date come from, and why is there no estimate?
A confirmed date comes from the company's own announcement. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so AlphaAI shows nothing until the company confirms. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.